Menu Back toS42-Think-About-Informed-Consent-from-a-Patient-s-Perspective-What-Can-We-Do-to-Promote-Proper-Understanding-of-Clinical-Trials-and-PatientFriendly-Clinical-Trials

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S42] Think About Informed Consent from a Patient’s Perspective – What Can We Do to Promote Proper Understanding of Clinical Trials and PatientFriendly Clinical Trials?

Session Chair(s)

Kazuo  Hasegawa

Kazuo Hasegawa

  • Representative Director
  • OnestepLung Cancer Patient Network ONE STEP, Japan
Informed consent is the first important process for patients to learn about and understand clinical trials. Recently, volume and complexity of Informed consent documents are increasing. In this session, we will discuss how we can improve informed consent documents and communication from a patient’s perspective based on the recent efforts in Japan and global.


David  Leventhal, MBA

Bringing Patient Centricity to Informed Consent and Promoting Understanding of Clinical Research Participation

David Leventhal, MBA

  • Senior Director, Clinical Trial Experience
  • Pfizer Inc, United States
Yumiko  Miyazaki, MSc

How Do We Make “Easy-to-Understand ICF” Come True?

Yumiko Miyazaki, MSc

  • Manager, Clinical Innovations & Business Integration,
  • Eli Lilly Japan K.K., Japan
Yukari  Suzuki, RN

From the Standpoint of CRC That Uses Various ICFs and Supports Many Subjects

Yukari Suzuki, RN

  • Chief Clinical Research Coordinator, Clinical and Translational Research Center
  • Nigata University Medical and Dental Hospital, Japan
Shinsuke  Amano

Shinsuke Amano

  • Director
  • Group Nexus Japan, Japan